CLK1 is known to influence the alternative splicing of genes involved in the cell cycle and is often overexpressed in breast cancer; its pharmacological inhibition can disrupt splicing and hinder tumor growth (Liu et al., 2025; Zhu et al., 2018). This evidence concerns the gene CLK1 and breast carcinoma.